Who Discovered TB-500? The Full Story

Who discovered TB-500? The honest answer has two parts. Teresa Low, Shu-Kuang Hu, and Allan Goldstein at George Washington University identified and sequenced thymosin beta-4 in 1981. TB-500 came later: FDA now uses that name for a synthetic seven-amino-acid fragment of the 43-amino-acid parent peptide. The published record does not identify one person who invented the TB-500 name.

That distinction matters. The original molecule, the short fragment, and the label on an online vial are not automatically the same thing.

Who discovered TB-500? Start with thymosin beta-4

Low, Hu, and Goldstein were studying the thymus, an organ involved in immune-cell development. They were not looking for a sports or recovery compound. Their starting material was thymosin fraction 5, a mixture of small molecules extracted from calf thymus.

In a 1981 PNAS paper, the George Washington University team reported the complete sequence of one member of that mixture: thymosin beta-4, a peptide made of 43 amino acids, the building blocks of proteins. The paper's experiments focused on immature immune cells in mice. That was the discovery moment for the parent molecule, not for a modern TB-500 product.

A decade later, David Safer, Michael Elzinga, and Vivianne Nachmias at the University of Pennsylvania solved a different part of the story. Their 1991 paper showed that a platelet molecule called Fx was actually thymosin beta-4. It bound actin, a protein cells use to hold their shape and move, and kept free actin from forming filaments too soon. That finding shifted the molecule's story from a supposed thymus hormone toward a widely distributed regulator inside cells.

How the TB-500 name appeared

The short fragment entered the literature in 2003, when Deborah Philp and colleagues studied a seven-amino-acid actin-binding sequence from thymosin beta-4. Their work concerned laboratory and animal models, not a medicine called TB-500. FDA's 2026 review says the fragment appears to have first been synthesized that year.

The name became chemically clearer in 2012. Simone Esposito's group at Ghent University's doping-control laboratory analyzed material sold as TB-500 and identified it as Ac-LKKTETQ—amino acids 17 through 23 of thymosin beta-4 with an acetyl group, a small chemical cap, on the first amino acid.

The letters point back to thymosin beta, but no primary paper explains why the number 500 was chosen. FDA calls TB-500 a common name, not a standardized U.S. drug name, and says different salts and derivatives have appeared under it. That is why an online label can be less precise than it looks. The site's thymosin beta-4 explainer goes deeper on the two molecules.

What the first human studies actually tested

The early human data were for full-length thymosin beta-4, not the seven-amino-acid TB-500 fragment. That single sentence prevents most of the confusion around this history.

A 2010 phase 1 study gave intravenous synthetic thymosin beta-4 or placebo to four groups of 10 healthy volunteers. The published report describes infrequent mild or moderate adverse events and no serious adverse events. Its job was early safety and drug-level measurement, not proof that the peptide repaired injuries.

The same development period included topical products. A 2010 phase 2 report covered 73 people with venous leg ulcers who were randomized to full-length thymosin beta-4 gel or placebo. The investigators described the safety profile as comparable with placebo and said one concentration had the potential to speed healing. It was a wound-gel study, not a trial of injected TB-500.

In 2015, a separate trial randomized 72 people with moderate to severe dry eye to RGN-259, a full-length thymosin beta-4 eye drop, or placebo for 28 days. The paper reports that neither primary endpoint differed significantly, although some secondary measures did. An eye drop result cannot be carried over to an injected fragment.

The same boundary applies to the Wolverine peptide pairing: combining BPC-157 with TB-500 does not turn full-length thymosin beta-4 studies into evidence for the blend.

Where TB-500 stands today

As of September 18, 2026, the day this article was written, the newest major regulatory development was the July 23 FDA Pharmacy Compounding Advisory Committee meeting. The panel recommended TB-500 free base and acetate for the 503A bulk-substances list by a reported vote of 8–6 with one abstention. The recommendation was advice, not a final agency rule; the FDA meeting page explains that committee recommendations are nonbinding.

The evidence gap did not disappear with that vote. FDA's May 15, 2026 briefing document says it found no study in which TB-500 was administered to people by any route and no human exposure data for the fragment. The agency's review also distinguished the seven-amino-acid substance from the full-length parent used in the clinical studies above. The site's FDA peptide decision tracker follows what would have to happen next.

TB-500 has never been an FDA-approved product in the United States. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor. Regulatory status does not turn thin evidence into strong evidence, or strong evidence into thin evidence.

What a prescription route changes

A prescribed route cannot fill the missing human-data gap. It can make the product and the people responsible for it less anonymous. The prescription identifies what the provider ordered, a licensed U.S. compounding pharmacy supplies a labeled preparation, and there is a clinical contact if questions or side effects arise. That is a meaningful difference from a grey-market vial whose TB-500 label may not say whether it contains the short fragment, the full peptide, or a particular salt.

At Promise, a licensed provider reviews every request, and not everyone qualifies. The history is useful context; the provider's job is to decide whether a compounded prescription makes sense for the individual in front of them.